Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today is the first day for the exercise of Diagonal Bio AB's ("Diagonal Bio" or "the Company") warrants of series TO 1 ("TO 1") which were issued in connection with the preferential issue of units that the Company carried out earlier this year. The period lasts until June 26, 2024. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio for each TO 1 at a price of SEK 0,05 per share. Through full utilisation of TO 1, the Company will receive approximately SEK 2,25 million before issue costs. An information document is available on the respective websites of Diagonal Bio (www.diagonalbio.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).
In April 2024, Diagonal Bio carried out a rights issue which brought the Company approximately SEK 18 million before issue costs. Through the rights issue, 45.082.580 warrants of series TO 1 were issued. Each TO 1 entitles the holder to subscribe for one (1) new share in Diagonal Bio during the exercise period, which runs September 12-26, 2024. The exercise price for TO 1 has been set at SEK 0,05 per share. In the event of full utilisation of warrants of series TO 1, approximately SEK 2,25 million will be added to the Company before issue costs.
Complete terms and instructions for warrants of series TO 1 are available on the Company's website (www.diagonalbio.com). An information sheet containing summary information about the warrant exercise is also available on Diagonal Bio's, Sedermera Corporate Finance AB's (www.sedermera.se) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites.
TO 1 in short- Exercise price: Each TO 1 entitles the warrant holder to subscribe for one (1) new share in Diagonal Bio at a price of SEK 0.05 per share.
- Issue volume: There are 45.082.580 issued TO 1. At full utilisation of TO 1, Diagonal Bio receives approx. SEK 2,25 million before issue costs.
- Number of outstanding shares prior to warrant exercise: 400.636.419 shares.
- Short name and ISIN: TO 1 are traded at Nasdaq First North Growth Market under short name "DIABIO TO1" and with ISIN SE0021921517.
- 12 September 2024: Exercise period commences
- 24 September 2024: Last day of trading in TO 1
- 26 September 2024: Exercise period ends
- 27 September 2024: Planned date for publication of outcome of the exercise
- 11 October 2024: Planned date for change from interim shares to shares
Shares and share capital
Upon full utilisation of TO 1, the number of shares in Diagonal Bio will increase by 45.082.580 shares to a total of 445.718.999 shares and the share capital will increase by SEK 449.837,10 to SEK 4.447.415,00. The dilution at full utilisation amounts to approximately 10,1 percent of the capital and votes.
Advisors
In connection with the warrant exercise, Diagonal Bio has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70305 24 88
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.